Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141490 · ClinicalTrials.gov registry record · Phase 2
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02141490: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02141490 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141490, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Background: People with prostate, bladder, or kidney cancer often have their cancer spread (metastasize) to lymph nodes. It is important for your doctor to know if this has occurred but currently it can be hard to determine if this has occurred on standard imaging studies like computed tomography (CT) or magnetic resonance imaging (MRI). This study uses an agent called Ferumoxytol to identify lymph nodes that might be involved by cancer. Objective: \- To see how well Ferumoxytol can detect lymph node metastases in patients with prostate, bladder, or kidney cancer. Eligibility: -Adults over age 18 with prostate, bladder, or kidney cancer with lymph node involvement. Design: * Participants will be screened with a medical history. * Participants will have blood drawn and a physical exam. Their vital signs will be measured. They will answer questions about their health and current medications. * Participants should not have a history of iron overload or have an allergy to Ferumoxytol. * Participants will have a magnetic resonance imaging (MRI) scan. The scanner is a metal cylinder with a strong magnetic field. Participants will lie on a table that slides in and out of the scanner. They will have a standard sensor, known as a coil, wrapped around their abdomen to improve the scan. This is like a small blanket with wiring inside. Participants will need to lie still on the scanning table for about 1 hour. * Participants will have an ultrasound. This uses harmless sound waves to provide pictures of organs or tissues inside the body. * Participants will receive an injection of Ferumoxytol through an intravenous line. A very thin plastic tube will be inserted into a vein in order to inject the agent. * Participants will have another MRI and ultrasound 24 and 48 hours after injection. * The study will follow participants medical course for at least 1 year.
Interventions
- DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI)
- DRUG Ferumoxytol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-05-15 |
| Est. Completion | 2018-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141490
The ClinicalTrials.gov registry entry for NCT02141490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT02141490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02141490 about?
NCT02141490 is a clinical study titled "Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers". Background: People with prostate, bladder, or kidney cancer often have their cancer spread (metastasize) to lymph nodes. It is important for your doctor to know if this has occurred but currently it can be hard to determine if this has occurred on standard imaging studies like computed tomography (...
What is the current status of trial NCT02141490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2014-05-15. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT02141490?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST), Ferumoxytol (DRUG).
Who is sponsoring clinical trial NCT02141490?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.